Search Results

There are 6213 results for: content related to: Erlotinib-induced folliculitis decalvans

  1. You have full text access to this Open Access content
    Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib

    Cancer Science

    Volume 100, Issue 9, September 2009, Pages: 1701–1707, Kohji Noguchi, Haruka Kawahara, Airi Kaji, Kazuhiro Katayama, Junko Mitsuhashi and Yoshikazu Sugimoto

    Version of Record online : 12 MAY 2009, DOI: 10.1111/j.1349-7006.2009.01213.x

  2. You have free access to this content
    Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

    International Journal of Cancer

    Volume 137, Issue 6, 15 September 2015, Pages: 1446–1456, Qiaoli Zhao, Nadine Kretschmer, Rudolf Bauer and Thomas Efferth

    Version of Record online : 6 MAR 2015, DOI: 10.1002/ijc.29483

  3. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 2, April 2015, Pages: 232–239, Y. Emoto-Yamamoto, S. Iida, T. Kawanishi and M. Fukuoka

    Version of Record online : 17 NOV 2014, DOI: 10.1111/jcpt.12232

  4. You have full text access to this Open Access content
    Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case–control study

    Thoracic Cancer

    Volume 3, Issue 1, February 2012, Pages: 27–33, Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou and You Lu

    Version of Record online : 5 FEB 2012, DOI: 10.1111/j.1759-7714.2011.00087.x

  5. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

    PROTEOMICS

    Volume 15, Issue 2-3, January 2015, Pages: 340–355, Xu Zhang, Natalya Belkina, Harrys Kishore Charles Jacob, Tapan Maity, Romi Biswas, Abhilash Venugopalan, Patrick G. Shaw, Min-Sik Kim, Raghothama Chaerkady, Akhilesh Pandey and Udayan Guha

    Version of Record online : 15 JAN 2015, DOI: 10.1002/pmic.201400315

  6. Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 282–290, Dr Paul Frohna, Dr Jianfeng Lu, Dr Steve Eppler, Dr Marta Hamilton, Ms Julie Wolf, Dr Ashok Rakhit, Dr Jie Ling, Dr Saraswati R. Kenkare-Mitra and Dr Bert L. Lum

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005284193

  7. You have full text access to this Open Access content
    JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

    Cancer Science

    Volume 103, Issue 10, October 2012, Pages: 1795–1802, Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Ohashi, Saburo Takata, Mitsune Tanimoto and Katsuyuki Kiura

    Version of Record online : 23 JUL 2012, DOI: 10.1111/j.1349-7006.2012.02363.x

  8. ERLOTINIB ACTIVATES MITOCHONDRIAL DEATH PATHWAYS RELATED TO THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN THE HUMAN NON-SMALL CELL LUNG CANCER CELL LINE A549

    Clinical and Experimental Pharmacology and Physiology

    Volume 36, Issue 5-6, May/June 2009, Pages: 487–494, Xia Qian, Jing Li, Jianhua Ding, Zhiyuan Wang, Wenjing Zhang and Gang Hu

    Version of Record online : 8 OCT 2008, DOI: 10.1111/j.1440-1681.2008.05091.x

  9. You have free access to this content
    Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells

    British Journal of Pharmacology

    Volume 172, Issue 18, September 2015, Pages: 4560–4574, I Kretschmer, T Freudenberger, S Twarock and J W Fischer

    Version of Record online : 30 JUL 2015, DOI: 10.1111/bph.13240

  10. You have free access to this content
    Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

    Hepatology

    Volume 59, Issue 4, April 2014, Pages: 1577–1590, Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub and Kenneth K. Tanabe

    Version of Record online : 28 FEB 2014, DOI: 10.1002/hep.26898

  11. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 9, September 2013, Pages: 1323–1330, Christina I. Tsien, Mukesh K. Nyati, Aarif Ahsan, Susmita G. Ramanand, Douglas B. Chepeha, Francis P. Worden, Joseph I. Helman, Nisha D'Silva, Carol R. Bradford, Gregory T. Wolf, Theodore S. Lawrence and Avraham Eisbruch

    Version of Record online : 21 AUG 2012, DOI: 10.1002/hed.23128

  12. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 6, June 2013, Pages: 809–818, Fabienne Thomas, Paul Delmar, Sébastien Vergez, Philippe Rochaix, Isabelle Hennebelle, Patricia McLoughlin, Adil Benlyazid, Jérôme Sarini and Jean–Pierre Delord

    Version of Record online : 13 JUL 2012, DOI: 10.1002/hed.23036

  13. Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells

    Phytotherapy Research

    Volume 28, Issue 5, May 2014, Pages: 728–735, Yoshikane Yamauchi, Yotaro Izumi, Jun Yamamoto and Hiroaki Nomori

    Version of Record online : 13 AUG 2013, DOI: 10.1002/ptr.5056

  14. You have full text access to this Open Access content
    Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer

    Cancer Science

    Volume 104, Issue 10, October 2013, Pages: 1346–1352, Naomi Ono, Toshikazu Yamazaki, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyoaki Sakata, Atsushi Suda, Takuo Tsukuda, Toshiyuki Mio, Nobuya Ishii, Osamu Kondoh and Yuko Aoki

    Version of Record online : 20 AUG 2013, DOI: 10.1111/cas.12237

  15. You have full text access to this Open Access content
    Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

    Journal of Cellular and Molecular Medicine

    Volume 14, Issue 1-2, January-February 2010, Pages: 51–69, Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell and Barbara Klughammer

    Version of Record online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00991.x

  16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

    Intervention Review

    The Cochrane Library

    Janette Greenhalgh, Kerry Dwan, Angela Boland, Victoria Bates, Fabio Vecchio, Yenal Dundar, Pooja Jain and John A Green

    Published Online : 25 MAY 2016, DOI: 10.1002/14651858.CD010383.pub2

  17. You have free access to this content
    Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models

    International Journal of Cancer

    Volume 130, Issue 10, 15 May 2012, Pages: 2445–2454, Mi Young Cha, Kwang-Ok Lee, Mira Kim, Ji Yeon Song, Kyu Hang Lee, Jongmin Park, Yun Jung Chae, Young Hoon Kim, Kwee Hyun Suh, Gwan Sun Lee, Seung Bum Park and Maeng Sup Kim

    Version of Record online : 24 AUG 2011, DOI: 10.1002/ijc.26276

  18. You have free access to this content
    A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results

    BJU International

    Volume 106, Issue 3, August 2010, Pages: 349–354, Raj S. Pruthi, Matthew Nielsen, Samuel Heathcote, Eric M. Wallen, W. Kim Rathmell, Paul Godley, Young Whang, Julia Fielding, Heather Schultz, Gayle Grigson, Angela Smith and William Kim

    Version of Record online : 19 JAN 2010, DOI: 10.1111/j.1464-410X.2009.09101.x

  19. Impact of nutritional status on the pharmacokinetics of erlotinib in rats

    Biopharmaceutics & Drug Disposition

    Volume 36, Issue 6, September 2015, Pages: 373–384, A. Pérez-Pitarch, A. Nácher, V. Merino, A. Catalán-Latorre, N.V. Jiménez-Torres and M. Merino-Sanjuán

    Version of Record online : 16 APR 2015, DOI: 10.1002/bdd.1948

  20. You have free access to this content
    Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

    Cancer

    Volume 118, Issue 23, 1 December 2012, Pages: 5903–5911, Jonathan W. Goldman, Isett Laux, Feng Chai, Ronald E. Savage, Dora Ferrari, Edward G. Garmey, Richard G. Just and Lee S. Rosen

    Version of Record online : 17 MAY 2012, DOI: 10.1002/cncr.27575